Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Table 7 Safety of antiviral therapy in genotype 1b-infected patients according to treatment regimens

Parameter	GT1b patients, n = 11385	ASV + DCV, n = 135	LDV/SOF ± RBV, n = 2652	OBV/PTV/r + DSV ± RBV, n = 3685	GZR/EBR ± RBV, n = 2270	GLE/PIB, n = 1684	GLE/PIB + SOF + RBV, n = 3	SOF/VEL ± RBV, n = 931	VOX/VEL/SOF, n = 9
Therapy course, n (%)
According to schedule	11031 (96.9)	130 (96.3)	2549 (96.1)	3513 (95.3)	2245 (98.9)	1666 (98.9)	3 (100)	900 (96.7)	9 (100)
Discontinuation	134 (1.2)	5 (3.7)	27 (1)	60 (1.6)	18 (0.8)	8 (0.5)	0	16 (1.7)	0
Modification	151 (1.3)	0	62 (2.4)	76 (2.1)	1 (< 0.1)	3 (0.2)	0	9 (1)	0
No data	69 (0.6)	0	14 (0.5)	36 (1)	6 (0.3)	7 (0.4)	0	6 (0.6)	0
Patients with at least one AE, n (%)	2167 (19)	49 (36.3)	518 (19.5)	911 (24.7)	362 (15.9)	184 (10.9)	1 (33.3)	133 (14.3)	0
Serious adverse events, n (%)	123 (1.1)	7 (5.2)	27 (1)	59 (1.6)	11 (0.5)	5 (0.3)	0	14 (1.5)	0
AEs leading to treatment discontinuation, n (%)	82 (0.7)	2 (1.5)	20 (0.8)	47 (1.3)	7 (0.3)	4 (0.2)	0	2 (0.2)	0
Most common AEs (≥ 1%), n (%)
Weakness/fatigue	1073 (9.4)	20 (14.8)	409 (15.4)	395 (10.7)	141 (6.2)	57 (3.4)	0	46 (4.9)	0
Anemia	142 (1.2)	1 (0.7)	65 (2.5)	55 (1.5)	9 (0.4)	1 (0.1)	1 (33.3)	5 (0.5)	0
Sleep disorders	214 (1.9)	4 (3)	49 (1.8)	95 (2.6)	29 (1.3)	25 (1.5)	0	12 (1.3)	0
Skin lesions	106 (0.9)	6 (4.4)	24 (0.9)	41 (1.1)	10 (0.4)	13 (0.8)	0	12 (1.3)	0
Itchy skin	205 (1.8)	0	31 (1.2)	135 (3.7)	6 (0.3)	27 (1.6)	0	5 (0.5)	0
Diarrhea	83 (0.7)	4 (3)	20 (0.8)	32 (0.9)	17 (0.7)	4 (0.2)	0	6 (0.6)	0
Nausea	136 (1.2)	4 (3)	29 (1.1)	50 (1.4)	25 (1.1)	20 (1.2)	0	8 (0.9)	0
Headaches	306 (2.7)	5 (3.7)	87 (3.3)	95 (2.6)	60 (2.6)	45 (2.7)	0	13 (1.4)	0
Myalgia/arthralgia	166 (1.5)	5 (3.7)	27 (1)	65 (1.8)	45 (2)	13 (0.8)	0	11 (1.2)	0
Abdominal pain	159 (1.4)	10 (7.4)	27 (1)	45 (1.2)	41 (1.8)	22 (1.3)	0	14 (1.5)	0
Loss of appetite	52 (0.5)	3 (2.2)	6 (0.2)	24 (0.7)	9 (0.4)	4 (0.2)	0	6 (0.6)	0
AEs of particular interest (cirrhotics), n (%)	n = 2768	n = 55	n = 737	n = 1019	n = 380	n = 278	n = 1	n = 290	n = 3
Ascites	60 (2.2)	0	31 (4.2)	21 (2.1)	2 (0.5)	0	0	6 (2.1)	0
Encephalopathy	44 (1.6)	0	22 (3)	16 (1.6)	1 (0.3)	2 (0.7)	0	3 (1)	0
Gastrointestinal bleeding	16 (0.6)	0	10 (1.4)	4 (0.4)	0	0	0	2 (0.7)	0
Death, n (%)	64 (0.6)	0	19 (0.7)	18 (0.5)	9 (0.4)	5 (0.3)	0	13 (1.4)	0

AE: Adverse event; ASV: Asunaprevir; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; GLE: Glecaprevir; GT: Genotype; GZR: Grazoprevir; LDV: Ledipasvir; OBV: Ombitasvir; PIB: Pibrentasvir; PTV/r: Paritaprevir; RBV: Ribavirin; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.